# Aprocitentan

Drug · id `cardio:aprocitentan` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Tryvio

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

Aprocitentan is the medicine in Tryvio, a tablet. The US label calls it an endothelin receptor antagonist. The label lists, as its indication, the treatment of hypertension, to lower blood pressure, in combination with other blood pressure medicines, in adults whose blood pressure is not adequately controlled on other drugs, and says no controlled trials show that it lowers the risk of heart attacks or strokes. A boxed warning says it is contraindicated during pregnancy because it may cause fetal harm; that risk concerns the unborn child and is recorded separately. The atlas holds no trial results for it.

## Technical summary

RxNorm ingredient 2679059; the label UNII MZI81HV01P equals the ingredient's. MeSH has no descriptor for aprocitentan (an exact-label lookup returned an empty list on 2026-11-19). RxClass lists the FDA established pharmacologic class Endothelin Receptor Antagonist, and the label says the same. The atlas class page for endothelin receptor antagonists is not in the corpus yet, so the record files under the medicines front only. The label read is the Idorsia Pharmaceuticals Ltd label for Tryvio, application NDA217686, effective 2026-08-14 in openFDA; it is the only openFDA label returned for the ingredient, and Drugs@FDA lists one application with one product. The adult indication and the boxed warning (recipient: fetal) sit in separate claims and contexts. This page records the label indication, the class, the boxed-warning title and one sentence, and the mechanism sentence only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: The developing fetus, for a person taking aprocitentan during pregnancy, as described in a US label boxed warning

Recipient: Fetal; Population: The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Fetus during pregnancy; the passage read gives no gestational ages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label of Tryvio carries a boxed warning titled embryo-fetal toxicity. It says the medicine is contraindicated for use during pregnancy because it may cause fetal harm if used by pregnant patients.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Fetal; Population: The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Fetus during pregnancy; the passage read gives no gestational ages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records the boxed-warning title and its first statement only. The warning also tells prescribers what to do before, during and after treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-19
- Sources:
  1. Background: openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22dfe7a2ee-612c-4aba-834a-d68e6b59a0a6%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-19T00:29:57Z. Source state: Current. Version fingerprint: 3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818.
     How it applies: Application number of the label read, NDA217686.
  2. Background: openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22dfe7a2ee-612c-4aba-834a-d68e6b59a0a6%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-19T00:29:57Z. Source state: Current. Version fingerprint: 3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818.
     How it applies: Effective date of the label text read, 20260814.
  3. Supports: openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22dfe7a2ee-612c-4aba-834a-d68e6b59a0a6%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], title. Retrieved 2026-11-19T00:29:57Z. Source state: Current. Version fingerprint: 3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-APR-LB-09).
  4. Supports: openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22dfe7a2ee-612c-4aba-834a-d68e6b59a0a6%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], first sentence. Retrieved 2026-11-19T00:29:57Z. Source state: Current. Version fingerprint: 3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-APR-LB-10).

## Context: Adults with hypertension that is not adequately controlled on other drugs, as described in the US label of Tryvio

Recipient: Recipient not specified; Population: Adult patients with hypertension who are not adequately controlled on other drugs, taking the medicine in combination with other antihypertensive drugs, as the indications section of the label describes them. The passages read give no other age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Tryvio (aprocitentan tablets; Idorsia Pharmaceuticals Ltd, application NDA217686; the version dated 2026-08-14 in openFDA) calls the product an endothelin receptor antagonist. It lists the treatment of hypertension, to lower blood pressure, in combination with other antihypertensive drugs, in adult patients who are not adequately controlled on other drugs, as the indication. The label also says there are no controlled trials showing that the medicine reduces the risk of fatal and non-fatal cardiovascular events.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Adult patients with hypertension who are not adequately controlled on other drugs, taking the medicine in combination with other antihypertensive drugs, as the indications section of the label describes them. The passages read give no other age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The label also gives a boxed warning about the unborn child, recorded in a separate claim and context. Contraindications, other warnings, interactions, the lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-19
- Sources:
  1. Background: openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22dfe7a2ee-612c-4aba-834a-d68e6b59a0a6%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-19T00:29:57Z. Source state: Current. Version fingerprint: 3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818.
     How it applies: Application number of the label read, NDA217686.
  2. Background: openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22dfe7a2ee-612c-4aba-834a-d68e6b59a0a6%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-19T00:29:57Z. Source state: Current. Version fingerprint: 3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818.
     How it applies: Effective date of the label text read, 20260814.
  3. Supports: openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22dfe7a2ee-612c-4aba-834a-d68e6b59a0a6%22&limit=1>
     Locator: results\[0\].description\[0\], first sentence. Retrieved 2026-11-19T00:29:57Z. Source state: Current. Version fingerprint: 3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-APR-LB-04).
  4. Supports: openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22dfe7a2ee-612c-4aba-834a-d68e6b59a0a6%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], indication statement. Retrieved 2026-11-19T00:29:57Z. Source state: Current. Version fingerprint: 3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-APR-LB-05).
  5. Supports: openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22dfe7a2ee-612c-4aba-834a-d68e6b59a0a6%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], indication statement, population. Retrieved 2026-11-19T00:29:57Z. Source state: Current. Version fingerprint: 3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-APR-LB-06).
  6. Supports: openFDA drug label record for aprocitentan tablets (Tryvio), Idorsia Pharmaceuticals Ltd label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id dfe7a2ee-612c-4aba-834a-d68e6b59a0a6 (manufacturer Idorsia Pharmaceuticals Ltd, application NDA217686), returned on 2026-11-19. The label text is dated 2026-08-14 (effective\_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.) <https://api.fda.gov/drug/label.json?search=set_id:%22dfe7a2ee-612c-4aba-834a-d68e6b59a0a6%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], outcomes sentence. Retrieved 2026-11-19T00:29:57Z. Source state: Current. Version fingerprint: 3e34bdb496f14f2febe2052399118a441c9f54a9a7d8f3f9d89ad112eac17818.
     How it applies: Label passage quoted in the research quote table (Q-W4K28-APR-LB-07).

## Connected pages

- FDA label lists hypertension, to lower blood pressure, in combination with other antihypertensive drugs in adults not adequately controlled on other drugs, as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-tryvio-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: c495249777c7144244fa3a16ceee735712d1722cd0ba89328df67117a3159e10
Last substantive edit: 2026-11-19
Evidence last checked: 2026-11-19
